Excipient Engineering and Design to Improve Processing of Oral Controlled Release Formulations

WILMINGTON, Del., Oct. 31, 2022 (GLOBE NEWSWIRE) announced the United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research Office of New Drugs has accepted Ashland Viatel™ bioresorbable mPEG-PDLLA pharmaceutical excipient in the review cycle of the FDA Novel Excipient Review Pilot Program.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. The session discusses: Challenges faced when removing TiO2 from film coatings Aquarius TM TF. A reliable and effective alternative to TiO2 in film coatings Improved process economics with Aquarius Genesis TF high-solids TiO2-free film coating

Wilmington, Del., Oct. 3, 2022 - Ashland is introducing Klucel™ xtend hydroxypropyl cellulose (HPC) controlled release matrix former, designed to deliver unsurpassed process versatility and release profile efficiency. 
Until now, there were limited options for managing the release profile of formulations, especially high dose, controlled release formulations. Ashland’s step change klucel™ xtend HPC has been shown to match the release profile of hypromellose controlled-release formulations at half the polymer concentration. The highly reduced polymer concentration achievable with klucel™ xtend HPC offers the possibility of smaller pills or higher dosage, if necessary. This new excipient offers unrivaled versatility across a broad range of APIs in every manufacturing process: dry granulation, wet-granulation, direct compression, and holt-melt extrusion.

Wilmington, Del., June 20, 2023 - Ashland is introducing Polyplasdone™ Plus, a co-processed multifunctional direct compression superdisintegrant containing a glidant and lubricant. Saving time and simplifying development, the multifunctional disintegrant offers superior powder flow and lubrication during pharmaceutical manufacturing. This innovative product eliminates two manufacturing steps and simplifies equipment setup while simultaneously delivering improved tablet hardness and helping ensure the production of consistent, high-quality products in batch and continuous manufacturing.

Ashland offers a range of excipients and technologies, polymer expertise, and technical support for oral solids, liquids, and parenteral dosage forms. Our solutions include controlled release, binders, disintegrants, solubles, stabilizers, rheology modifiers, and resorbable polymers.

Ashland has raised the bar on its business-driven environment, social and governance (ESG) targets by demonstrating a clear link between its long-range strategic plans and detailed ESG progress.